A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

NCT04235959 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the medication tirzepatide in adults with type 2 diabetes in China.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 24 people

Who can join Ages 20–70 · all sexes

Timeline Started 2020-10 · est. completion 2021-08

Where 2 sites · China

What this study is testing ClinicalTrials.gov NCT04235959 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus. The study will also measure how much tirzepatide gets into the bloodstream and how long it takes the body to remove it. The study will last about six or eight months for each participant.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04235959 ↗